Dunn, Christopher J.; Foster, Rachel H. - In: PharmacoEconomics 16 (1999) 6, pp. 711-741
Abciximab is a monoclonal antibody fragment that inhibits platelet aggregation through antagonism of glycoprotein IIb/IIIa. The drug is used in conjunction with heparin and aspirin to prevent ischaemic complications associated with percutaneous coronary revascularisation in patients with...